nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—kidney cancer—melanoma	0.207	0.509	CtDrD
Erlotinib—lung cancer—melanoma	0.2	0.491	CtDrD
Erlotinib—CYP1B1—melanoma	0.0839	0.395	CbGaD
Erlotinib—EGFR—melanoma	0.0792	0.373	CbGaD
Erlotinib—EGFR—Docetaxel—melanoma	0.0387	0.165	CbGbCtD
Erlotinib—NR1I2—Docetaxel—melanoma	0.0352	0.151	CbGbCtD
Erlotinib—ORM1—Vemurafenib—melanoma	0.0305	0.13	CbGbCtD
Erlotinib—ALB—melanoma	0.0252	0.119	CbGaD
Erlotinib—ABCB1—melanoma	0.0241	0.113	CbGaD
Erlotinib—ABCG2—Vemurafenib—melanoma	0.0186	0.0796	CbGbCtD
Erlotinib—CYP1B1—Docetaxel—melanoma	0.0134	0.0575	CbGbCtD
Erlotinib—CYP1A1—Dacarbazine—melanoma	0.0132	0.0563	CbGbCtD
Erlotinib—ALB—Vemurafenib—melanoma	0.0128	0.0549	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—melanoma	0.0124	0.0529	CbGbCtD
Erlotinib—CYP1A2—Carmustine—melanoma	0.00971	0.0415	CbGbCtD
Erlotinib—CYP1A2—Vemurafenib—melanoma	0.00767	0.0328	CbGbCtD
Erlotinib—CYP3A4—Temozolomide—melanoma	0.00734	0.0314	CbGbCtD
Erlotinib—ABCG2—Docetaxel—melanoma	0.00638	0.0273	CbGbCtD
Erlotinib—CYP2D6—Vemurafenib—melanoma	0.00632	0.027	CbGbCtD
Erlotinib—CYP1A2—Dacarbazine—melanoma	0.00588	0.0252	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—melanoma	0.00446	0.0191	CbGbCtD
Erlotinib—CYP3A4—Vemurafenib—melanoma	0.00402	0.0172	CbGbCtD
Erlotinib—CYP3A5—Docetaxel—melanoma	0.00354	0.0151	CbGbCtD
Erlotinib—ABCB1—Docetaxel—melanoma	0.0023	0.00985	CbGbCtD
Erlotinib—CYP3A4—Docetaxel—melanoma	0.00138	0.0059	CbGbCtD
Erlotinib—MKNK1—hair follicle—melanoma	0.000766	0.0532	CbGeAlD
Erlotinib—TNK1—mammalian vulva—melanoma	0.000435	0.0302	CbGeAlD
Erlotinib—LTK—head—melanoma	0.000424	0.0294	CbGeAlD
Erlotinib—NR1I2—head—melanoma	0.000424	0.0294	CbGeAlD
Erlotinib—PIP4K2C—retina—melanoma	0.000421	0.0293	CbGeAlD
Erlotinib—Vandetanib—KDR—melanoma	0.000409	0.257	CrCbGaD
Erlotinib—ULK3—eye—melanoma	0.000406	0.0282	CbGeAlD
Erlotinib—ULK3—retina—melanoma	0.000402	0.0279	CbGeAlD
Erlotinib—MKNK1—eye—melanoma	0.000382	0.0265	CbGeAlD
Erlotinib—MKNK1—retina—melanoma	0.000379	0.0263	CbGeAlD
Erlotinib—CYP1B1—hair follicle—melanoma	0.000368	0.0255	CbGeAlD
Erlotinib—AURKC—head—melanoma	0.000366	0.0254	CbGeAlD
Erlotinib—CYP1A1—skin epidermis—melanoma	0.000364	0.0253	CbGeAlD
Erlotinib—EGFR—mammalian vulva—melanoma	0.000348	0.0242	CbGeAlD
Erlotinib—Vandetanib—VEGFA—melanoma	0.000347	0.218	CrCbGaD
Erlotinib—JAK3—head—melanoma	0.000339	0.0235	CbGeAlD
Erlotinib—EPHA6—head—melanoma	0.000339	0.0235	CbGeAlD
Erlotinib—PIP4K2C—mammalian vulva—melanoma	0.000337	0.0234	CbGeAlD
Erlotinib—ULK3—mammalian vulva—melanoma	0.000322	0.0224	CbGeAlD
Erlotinib—MAP3K19—head—melanoma	0.000308	0.0214	CbGeAlD
Erlotinib—MKNK1—mammalian vulva—melanoma	0.000303	0.0211	CbGeAlD
Erlotinib—LTK—lymph node—melanoma	0.000297	0.0206	CbGeAlD
Erlotinib—Vandetanib—EGFR—melanoma	0.000293	0.184	CrCbGaD
Erlotinib—SLK—mammalian vulva—melanoma	0.000287	0.0199	CbGeAlD
Erlotinib—Gefitinib—EGFR—melanoma	0.000278	0.175	CrCbGaD
Erlotinib—AURKC—lymph node—melanoma	0.000256	0.0178	CbGeAlD
Erlotinib—STK10—mammalian vulva—melanoma	0.00025	0.0173	CbGeAlD
Erlotinib—PIP4K2C—head—melanoma	0.000241	0.0168	CbGeAlD
Erlotinib—JAK3—lymph node—melanoma	0.000237	0.0165	CbGeAlD
Erlotinib—ULK3—head—melanoma	0.00023	0.016	CbGeAlD
Erlotinib—MAP2K5—mammalian vulva—melanoma	0.000223	0.0155	CbGeAlD
Erlotinib—TNK1—lymph node—melanoma	0.000218	0.0151	CbGeAlD
Erlotinib—MKNK1—head—melanoma	0.000217	0.0151	CbGeAlD
Erlotinib—ABL1—eye—melanoma	0.000217	0.0151	CbGeAlD
Erlotinib—ABL1—retina—melanoma	0.000215	0.0149	CbGeAlD
Erlotinib—ABL1—skin of body—melanoma	0.000189	0.0131	CbGeAlD
Erlotinib—FLT3—lymph node—melanoma	0.000187	0.013	CbGeAlD
Erlotinib—CYP1B1—eye—melanoma	0.000184	0.0127	CbGeAlD
Erlotinib—ABL2—lymph node—melanoma	0.000179	0.0124	CbGeAlD
Erlotinib—STK10—head—melanoma	0.000179	0.0124	CbGeAlD
Erlotinib—EGFR—lymph node—melanoma	0.000174	0.0121	CbGeAlD
Erlotinib—ABL1—mammalian vulva—melanoma	0.000172	0.0119	CbGeAlD
Erlotinib—PIP4K2C—lymph node—melanoma	0.000169	0.0117	CbGeAlD
Erlotinib—ULK3—lymph node—melanoma	0.000161	0.0112	CbGeAlD
Erlotinib—CYP1B1—skin of body—melanoma	0.00016	0.0111	CbGeAlD
Erlotinib—MAP2K5—head—melanoma	0.000159	0.0111	CbGeAlD
Erlotinib—Dry skin—Temozolomide—melanoma	0.000155	0.00275	CcSEcCtD
Erlotinib—Hepatocellular injury—Docetaxel—melanoma	0.000155	0.00275	CcSEcCtD
Erlotinib—Hypokalaemia—Temozolomide—melanoma	0.000154	0.00273	CcSEcCtD
Erlotinib—Acute coronary syndrome—Bleomycin—melanoma	0.000152	0.00271	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Temozolomide—melanoma	0.000152	0.00271	CcSEcCtD
Erlotinib—MKNK1—lymph node—melanoma	0.000152	0.0105	CbGeAlD
Erlotinib—Myocardial infarction—Bleomycin—melanoma	0.000151	0.00269	CcSEcCtD
Erlotinib—Dysphagia—Carmustine—melanoma	0.000151	0.00269	CcSEcCtD
Erlotinib—Neutropenia—Dactinomycin—melanoma	0.000151	0.00269	CcSEcCtD
Erlotinib—Stomatitis—Bleomycin—melanoma	0.00015	0.00268	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000149	0.00265	CcSEcCtD
Erlotinib—Colitis—Docetaxel—melanoma	0.000148	0.00264	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000148	0.00263	CcSEcCtD
Erlotinib—Skin exfoliation—Docetaxel—melanoma	0.000148	0.00263	CcSEcCtD
Erlotinib—Dysphagia—Temozolomide—melanoma	0.000146	0.0026	CcSEcCtD
Erlotinib—Neuropathy—Docetaxel—melanoma	0.000145	0.00258	CcSEcCtD
Erlotinib—Pneumonia—Dactinomycin—melanoma	0.000145	0.00258	CcSEcCtD
Erlotinib—SLK—lymph node—melanoma	0.000144	0.00999	CbGeAlD
Erlotinib—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000142	0.00254	CcSEcCtD
Erlotinib—Neutropenia—Carmustine—melanoma	0.000141	0.00251	CcSEcCtD
Erlotinib—Decreased appetite—Vemurafenib—melanoma	0.000141	0.00251	CcSEcCtD
Erlotinib—Stomatitis—Dactinomycin—melanoma	0.00014	0.0025	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Vemurafenib—melanoma	0.00014	0.00249	CcSEcCtD
Erlotinib—Fatigue—Vemurafenib—melanoma	0.00014	0.00249	CcSEcCtD
Erlotinib—Haemoglobin—Bleomycin—melanoma	0.000139	0.00248	CcSEcCtD
Erlotinib—Constipation—Vemurafenib—melanoma	0.000139	0.00247	CcSEcCtD
Erlotinib—Haemorrhage—Bleomycin—melanoma	0.000138	0.00246	CcSEcCtD
Erlotinib—Neutropenia—Temozolomide—melanoma	0.000136	0.00243	CcSEcCtD
Erlotinib—Pneumonia—Carmustine—melanoma	0.000135	0.00241	CcSEcCtD
Erlotinib—Depression—Carmustine—melanoma	0.000134	0.00239	CcSEcCtD
Erlotinib—Sepsis—Docetaxel—melanoma	0.000134	0.00239	CcSEcCtD
Erlotinib—Renal failure—Carmustine—melanoma	0.000132	0.00236	CcSEcCtD
Erlotinib—Weight decreased—Temozolomide—melanoma	0.000132	0.00235	CcSEcCtD
Erlotinib—Neuropathy peripheral—Carmustine—melanoma	0.000132	0.00235	CcSEcCtD
Erlotinib—Stomatitis—Carmustine—melanoma	0.000131	0.00234	CcSEcCtD
Erlotinib—Pneumonia—Temozolomide—melanoma	0.000131	0.00233	CcSEcCtD
Erlotinib—Infestation NOS—Temozolomide—melanoma	0.00013	0.00232	CcSEcCtD
Erlotinib—Infestation—Temozolomide—melanoma	0.00013	0.00232	CcSEcCtD
Erlotinib—Depression—Temozolomide—melanoma	0.00013	0.00231	CcSEcCtD
Erlotinib—Hepatitis—Dactinomycin—melanoma	0.000129	0.0023	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Temozolomide—melanoma	0.000129	0.0023	CcSEcCtD
Erlotinib—Body temperature increased—Vemurafenib—melanoma	0.000128	0.00228	CcSEcCtD
Erlotinib—Neuropathy peripheral—Temozolomide—melanoma	0.000127	0.00227	CcSEcCtD
Erlotinib—Stomatitis—Temozolomide—melanoma	0.000127	0.00226	CcSEcCtD
Erlotinib—ABCB1—blood vessel—melanoma	0.000127	0.0088	CbGeAlD
Erlotinib—STK10—lymph node—melanoma	0.000125	0.00868	CbGeAlD
Erlotinib—Hepatic failure—Docetaxel—melanoma	0.000125	0.00222	CcSEcCtD
Erlotinib—Chills—Bleomycin—melanoma	0.000124	0.00221	CcSEcCtD
Erlotinib—SLCO2B1—head—melanoma	0.000124	0.00862	CbGeAlD
Erlotinib—ABL1—head—melanoma	0.000123	0.00854	CbGeAlD
Erlotinib—Hepatobiliary disease—Temozolomide—melanoma	0.000123	0.00219	CcSEcCtD
Erlotinib—Alopecia—Bleomycin—melanoma	0.000122	0.00218	CcSEcCtD
Erlotinib—Erythema multiforme—Dactinomycin—melanoma	0.000122	0.00217	CcSEcCtD
Erlotinib—Haemoglobin—Carmustine—melanoma	0.000121	0.00216	CcSEcCtD
Erlotinib—Haemorrhage—Carmustine—melanoma	0.000121	0.00215	CcSEcCtD
Erlotinib—Erythema—Bleomycin—melanoma	0.00012	0.00215	CcSEcCtD
Erlotinib—Connective tissue disorder—Carmustine—melanoma	0.000119	0.00211	CcSEcCtD
Erlotinib—Renal impairment—Docetaxel—melanoma	0.000118	0.0021	CcSEcCtD
Erlotinib—Dermatitis bullous—Docetaxel—melanoma	0.000117	0.00209	CcSEcCtD
Erlotinib—Haemoglobin—Temozolomide—melanoma	0.000117	0.00209	CcSEcCtD
Erlotinib—Haemorrhage—Temozolomide—melanoma	0.000117	0.00208	CcSEcCtD
Erlotinib—Hepatitis—Temozolomide—melanoma	0.000117	0.00208	CcSEcCtD
Erlotinib—Asthenia—Vemurafenib—melanoma	0.000116	0.00207	CcSEcCtD
Erlotinib—Chills—Dactinomycin—melanoma	0.000116	0.00206	CcSEcCtD
Erlotinib—Urinary tract disorder—Temozolomide—melanoma	0.000115	0.00205	CcSEcCtD
Erlotinib—Pruritus—Vemurafenib—melanoma	0.000115	0.00204	CcSEcCtD
Erlotinib—Connective tissue disorder—Temozolomide—melanoma	0.000115	0.00204	CcSEcCtD
Erlotinib—Urethral disorder—Temozolomide—melanoma	0.000114	0.00204	CcSEcCtD
Erlotinib—Alopecia—Dactinomycin—melanoma	0.000114	0.00203	CcSEcCtD
Erlotinib—CYP1A1—skin of body—melanoma	0.000113	0.00784	CbGeAlD
Erlotinib—Eye disorder—Carmustine—melanoma	0.000113	0.00201	CcSEcCtD
Erlotinib—Erythema—Dactinomycin—melanoma	0.000112	0.002	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000112	0.002	CcSEcCtD
Erlotinib—MAP2K5—lymph node—melanoma	0.000112	0.00776	CbGeAlD
Erlotinib—Diarrhoea—Vemurafenib—melanoma	0.000111	0.00198	CcSEcCtD
Erlotinib—Erythema multiforme—Temozolomide—melanoma	0.00011	0.00197	CcSEcCtD
Erlotinib—Eye disorder—Temozolomide—melanoma	0.000109	0.00194	CcSEcCtD
Erlotinib—ABCG2—mammalian vulva—melanoma	0.000108	0.00753	CbGeAlD
Erlotinib—Arrhythmia—Carmustine—melanoma	0.000108	0.00192	CcSEcCtD
Erlotinib—Dizziness—Vemurafenib—melanoma	0.000107	0.00191	CcSEcCtD
Erlotinib—Alopecia—Carmustine—melanoma	0.000107	0.0019	CcSEcCtD
Erlotinib—Mental disorder—Carmustine—melanoma	0.000106	0.00188	CcSEcCtD
Erlotinib—Mediastinal disorder—Temozolomide—melanoma	0.000105	0.00187	CcSEcCtD
Erlotinib—Malnutrition—Carmustine—melanoma	0.000105	0.00187	CcSEcCtD
Erlotinib—Erythema—Carmustine—melanoma	0.000105	0.00187	CcSEcCtD
Erlotinib—Cough—Bleomycin—melanoma	0.000105	0.00187	CcSEcCtD
Erlotinib—Chills—Temozolomide—melanoma	0.000105	0.00187	CcSEcCtD
Erlotinib—Dehydration—Docetaxel—melanoma	0.000104	0.00186	CcSEcCtD
Erlotinib—CYP1B1—head—melanoma	0.000104	0.00724	CbGeAlD
Erlotinib—Vomiting—Vemurafenib—melanoma	0.000103	0.00184	CcSEcCtD
Erlotinib—Alopecia—Temozolomide—melanoma	0.000103	0.00184	CcSEcCtD
Erlotinib—CYP1A1—mammalian vulva—melanoma	0.000103	0.00715	CbGeAlD
Erlotinib—Dry skin—Docetaxel—melanoma	0.000103	0.00183	CcSEcCtD
Erlotinib—Chest pain—Bleomycin—melanoma	0.000103	0.00183	CcSEcCtD
Erlotinib—Myalgia—Bleomycin—melanoma	0.000103	0.00183	CcSEcCtD
Erlotinib—Rash—Vemurafenib—melanoma	0.000102	0.00182	CcSEcCtD
Erlotinib—Mental disorder—Temozolomide—melanoma	0.000102	0.00182	CcSEcCtD
Erlotinib—Dermatitis—Vemurafenib—melanoma	0.000102	0.00182	CcSEcCtD
Erlotinib—Back pain—Carmustine—melanoma	0.000102	0.00181	CcSEcCtD
Erlotinib—Headache—Vemurafenib—melanoma	0.000102	0.00181	CcSEcCtD
Erlotinib—Malnutrition—Temozolomide—melanoma	0.000102	0.00181	CcSEcCtD
Erlotinib—Erythema—Temozolomide—melanoma	0.000102	0.00181	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000101	0.0018	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Docetaxel—melanoma	9.89e-05	0.00176	CcSEcCtD
Erlotinib—Oedema—Bleomycin—melanoma	9.83e-05	0.00175	CcSEcCtD
Erlotinib—Back pain—Temozolomide—melanoma	9.83e-05	0.00175	CcSEcCtD
Erlotinib—Infection—Bleomycin—melanoma	9.76e-05	0.00174	CcSEcCtD
Erlotinib—Dysphagia—Docetaxel—melanoma	9.7e-05	0.00173	CcSEcCtD
Erlotinib—Nausea—Vemurafenib—melanoma	9.64e-05	0.00172	CcSEcCtD
Erlotinib—Thrombocytopenia—Bleomycin—melanoma	9.62e-05	0.00171	CcSEcCtD
Erlotinib—Myalgia—Dactinomycin—melanoma	9.56e-05	0.0017	CcSEcCtD
Erlotinib—Anorexia—Bleomycin—melanoma	9.37e-05	0.00167	CcSEcCtD
Erlotinib—Vandetanib—ALB—melanoma	9.32e-05	0.0585	CrCbGaD
Erlotinib—Oedema—Dactinomycin—melanoma	9.17e-05	0.00163	CcSEcCtD
Erlotinib—Infection—Dactinomycin—melanoma	9.11e-05	0.00162	CcSEcCtD
Erlotinib—ORM1—lymph node—melanoma	9.07e-05	0.0063	CbGeAlD
Erlotinib—Neutropenia—Docetaxel—melanoma	9.07e-05	0.00162	CcSEcCtD
Erlotinib—Thrombocytopenia—Dactinomycin—melanoma	8.98e-05	0.0016	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Bleomycin—melanoma	8.95e-05	0.0016	CcSEcCtD
Erlotinib—Myalgia—Carmustine—melanoma	8.95e-05	0.00159	CcSEcCtD
Erlotinib—Chest pain—Carmustine—melanoma	8.95e-05	0.00159	CcSEcCtD
Erlotinib—Anxiety—Carmustine—melanoma	8.92e-05	0.00159	CcSEcCtD
Erlotinib—Cough—Temozolomide—melanoma	8.86e-05	0.00158	CcSEcCtD
Erlotinib—Gefitinib—ALB—melanoma	8.86e-05	0.0556	CrCbGaD
Erlotinib—Weight decreased—Docetaxel—melanoma	8.77e-05	0.00156	CcSEcCtD
Erlotinib—Dyspnoea—Bleomycin—melanoma	8.76e-05	0.00156	CcSEcCtD
Erlotinib—Anorexia—Dactinomycin—melanoma	8.74e-05	0.00156	CcSEcCtD
Erlotinib—Pneumonia—Docetaxel—melanoma	8.7e-05	0.00155	CcSEcCtD
Erlotinib—SLCO2B1—lymph node—melanoma	8.69e-05	0.00604	CbGeAlD
Erlotinib—Arthralgia—Temozolomide—melanoma	8.65e-05	0.00154	CcSEcCtD
Erlotinib—Myalgia—Temozolomide—melanoma	8.65e-05	0.00154	CcSEcCtD
Erlotinib—Infestation—Docetaxel—melanoma	8.64e-05	0.00154	CcSEcCtD
Erlotinib—Infestation NOS—Docetaxel—melanoma	8.64e-05	0.00154	CcSEcCtD
Erlotinib—Anxiety—Temozolomide—melanoma	8.62e-05	0.00154	CcSEcCtD
Erlotinib—ABL1—lymph node—melanoma	8.62e-05	0.00598	CbGeAlD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	8.59e-05	0.00153	CcSEcCtD
Erlotinib—Oedema—Carmustine—melanoma	8.58e-05	0.00153	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Docetaxel—melanoma	8.57e-05	0.00153	CcSEcCtD
Erlotinib—Decreased appetite—Bleomycin—melanoma	8.54e-05	0.00152	CcSEcCtD
Erlotinib—Infection—Carmustine—melanoma	8.52e-05	0.00152	CcSEcCtD
Erlotinib—Acute coronary syndrome—Docetaxel—melanoma	8.52e-05	0.00152	CcSEcCtD
Erlotinib—Renal failure—Docetaxel—melanoma	8.5e-05	0.00151	CcSEcCtD
Erlotinib—Myocardial infarction—Docetaxel—melanoma	8.47e-05	0.00151	CcSEcCtD
Erlotinib—Neuropathy peripheral—Docetaxel—melanoma	8.47e-05	0.00151	CcSEcCtD
Erlotinib—Gefitinib—ABCB1—melanoma	8.45e-05	0.0531	CrCbGaD
Erlotinib—Stomatitis—Docetaxel—melanoma	8.43e-05	0.0015	CcSEcCtD
Erlotinib—Pain—Bleomycin—melanoma	8.4e-05	0.0015	CcSEcCtD
Erlotinib—Conjunctivitis—Docetaxel—melanoma	8.4e-05	0.0015	CcSEcCtD
Erlotinib—Thrombocytopenia—Carmustine—melanoma	8.4e-05	0.0015	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dactinomycin—melanoma	8.35e-05	0.00149	CcSEcCtD
Erlotinib—Oedema—Temozolomide—melanoma	8.29e-05	0.00148	CcSEcCtD
Erlotinib—Infection—Temozolomide—melanoma	8.24e-05	0.00147	CcSEcCtD
Erlotinib—Anorexia—Carmustine—melanoma	8.18e-05	0.00146	CcSEcCtD
Erlotinib—Hepatobiliary disease—Docetaxel—melanoma	8.18e-05	0.00146	CcSEcCtD
Erlotinib—Epistaxis—Docetaxel—melanoma	8.15e-05	0.00145	CcSEcCtD
Erlotinib—Nervous system disorder—Temozolomide—melanoma	8.13e-05	0.00145	CcSEcCtD
Erlotinib—Thrombocytopenia—Temozolomide—melanoma	8.12e-05	0.00145	CcSEcCtD
Erlotinib—Skin disorder—Temozolomide—melanoma	8.05e-05	0.00143	CcSEcCtD
Erlotinib—Decreased appetite—Dactinomycin—melanoma	7.97e-05	0.00142	CcSEcCtD
Erlotinib—ALB—lymph node—melanoma	7.95e-05	0.00552	CbGeAlD
Erlotinib—Fatigue—Dactinomycin—melanoma	7.9e-05	0.00141	CcSEcCtD
Erlotinib—Anorexia—Temozolomide—melanoma	7.9e-05	0.00141	CcSEcCtD
Erlotinib—Pain—Dactinomycin—melanoma	7.84e-05	0.0014	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Carmustine—melanoma	7.82e-05	0.00139	CcSEcCtD
Erlotinib—Haemoglobin—Docetaxel—melanoma	7.8e-05	0.00139	CcSEcCtD
Erlotinib—Body temperature increased—Bleomycin—melanoma	7.77e-05	0.00138	CcSEcCtD
Erlotinib—Haemorrhage—Docetaxel—melanoma	7.76e-05	0.00138	CcSEcCtD
Erlotinib—Hepatitis—Docetaxel—melanoma	7.76e-05	0.00138	CcSEcCtD
Erlotinib—Insomnia—Carmustine—melanoma	7.76e-05	0.00138	CcSEcCtD
Erlotinib—Urinary tract disorder—Docetaxel—melanoma	7.66e-05	0.00137	CcSEcCtD
Erlotinib—Dyspnoea—Carmustine—melanoma	7.65e-05	0.00136	CcSEcCtD
Erlotinib—Connective tissue disorder—Docetaxel—melanoma	7.63e-05	0.00136	CcSEcCtD
Erlotinib—Urethral disorder—Docetaxel—melanoma	7.61e-05	0.00136	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Temozolomide—melanoma	7.55e-05	0.00135	CcSEcCtD
Erlotinib—Insomnia—Temozolomide—melanoma	7.5e-05	0.00134	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dactinomycin—melanoma	7.5e-05	0.00134	CcSEcCtD
Erlotinib—Decreased appetite—Carmustine—melanoma	7.46e-05	0.00133	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Carmustine—melanoma	7.41e-05	0.00132	CcSEcCtD
Erlotinib—Dyspnoea—Temozolomide—melanoma	7.39e-05	0.00132	CcSEcCtD
Erlotinib—CYP1A1—head—melanoma	7.37e-05	0.00512	CbGeAlD
Erlotinib—Erythema multiforme—Docetaxel—melanoma	7.34e-05	0.00131	CcSEcCtD
Erlotinib—Pain—Carmustine—melanoma	7.34e-05	0.00131	CcSEcCtD
Erlotinib—Constipation—Carmustine—melanoma	7.34e-05	0.00131	CcSEcCtD
Erlotinib—Dyspepsia—Temozolomide—melanoma	7.3e-05	0.0013	CcSEcCtD
Erlotinib—CYP1B1—lymph node—melanoma	7.3e-05	0.00507	CbGeAlD
Erlotinib—Eye disorder—Docetaxel—melanoma	7.25e-05	0.00129	CcSEcCtD
Erlotinib—Abdominal pain—Dactinomycin—melanoma	7.25e-05	0.00129	CcSEcCtD
Erlotinib—Body temperature increased—Dactinomycin—melanoma	7.25e-05	0.00129	CcSEcCtD
Erlotinib—Decreased appetite—Temozolomide—melanoma	7.21e-05	0.00128	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Temozolomide—melanoma	7.16e-05	0.00128	CcSEcCtD
Erlotinib—Fatigue—Temozolomide—melanoma	7.15e-05	0.00127	CcSEcCtD
Erlotinib—Pain—Temozolomide—melanoma	7.09e-05	0.00126	CcSEcCtD
Erlotinib—Constipation—Temozolomide—melanoma	7.09e-05	0.00126	CcSEcCtD
Erlotinib—Asthenia—Bleomycin—melanoma	7.05e-05	0.00126	CcSEcCtD
Erlotinib—Gastrointestinal pain—Carmustine—melanoma	7.02e-05	0.00125	CcSEcCtD
Erlotinib—Mediastinal disorder—Docetaxel—melanoma	6.99e-05	0.00125	CcSEcCtD
Erlotinib—Chills—Docetaxel—melanoma	6.96e-05	0.00124	CcSEcCtD
Erlotinib—Pruritus—Bleomycin—melanoma	6.95e-05	0.00124	CcSEcCtD
Erlotinib—Arrhythmia—Docetaxel—melanoma	6.93e-05	0.00124	CcSEcCtD
Erlotinib—Alopecia—Docetaxel—melanoma	6.86e-05	0.00122	CcSEcCtD
Erlotinib—Mental disorder—Docetaxel—melanoma	6.8e-05	0.00121	CcSEcCtD
Erlotinib—Abdominal pain—Carmustine—melanoma	6.78e-05	0.00121	CcSEcCtD
Erlotinib—Body temperature increased—Carmustine—melanoma	6.78e-05	0.00121	CcSEcCtD
Erlotinib—Gastrointestinal pain—Temozolomide—melanoma	6.78e-05	0.00121	CcSEcCtD
Erlotinib—Malnutrition—Docetaxel—melanoma	6.76e-05	0.0012	CcSEcCtD
Erlotinib—Erythema—Docetaxel—melanoma	6.76e-05	0.0012	CcSEcCtD
Erlotinib—ABCB1—retina—melanoma	6.68e-05	0.00464	CbGeAlD
Erlotinib—Asthenia—Dactinomycin—melanoma	6.58e-05	0.00117	CcSEcCtD
Erlotinib—Body temperature increased—Temozolomide—melanoma	6.55e-05	0.00117	CcSEcCtD
Erlotinib—Abdominal pain—Temozolomide—melanoma	6.55e-05	0.00117	CcSEcCtD
Erlotinib—Back pain—Docetaxel—melanoma	6.53e-05	0.00116	CcSEcCtD
Erlotinib—Diarrhoea—Dactinomycin—melanoma	6.27e-05	0.00112	CcSEcCtD
Erlotinib—Vomiting—Bleomycin—melanoma	6.25e-05	0.00111	CcSEcCtD
Erlotinib—Rash—Bleomycin—melanoma	6.2e-05	0.0011	CcSEcCtD
Erlotinib—Dermatitis—Bleomycin—melanoma	6.19e-05	0.0011	CcSEcCtD
Erlotinib—Asthenia—Carmustine—melanoma	6.16e-05	0.0011	CcSEcCtD
Erlotinib—Syncope—Docetaxel—melanoma	6.06e-05	0.00108	CcSEcCtD
Erlotinib—Asthenia—Temozolomide—melanoma	5.95e-05	0.00106	CcSEcCtD
Erlotinib—Loss of consciousness—Docetaxel—melanoma	5.94e-05	0.00106	CcSEcCtD
Erlotinib—Cough—Docetaxel—melanoma	5.9e-05	0.00105	CcSEcCtD
Erlotinib—Diarrhoea—Carmustine—melanoma	5.87e-05	0.00105	CcSEcCtD
Erlotinib—Pruritus—Temozolomide—melanoma	5.87e-05	0.00104	CcSEcCtD
Erlotinib—Nausea—Bleomycin—melanoma	5.84e-05	0.00104	CcSEcCtD
Erlotinib—Vomiting—Dactinomycin—melanoma	5.83e-05	0.00104	CcSEcCtD
Erlotinib—Rash—Dactinomycin—melanoma	5.78e-05	0.00103	CcSEcCtD
Erlotinib—Myalgia—Docetaxel—melanoma	5.75e-05	0.00102	CcSEcCtD
Erlotinib—Chest pain—Docetaxel—melanoma	5.75e-05	0.00102	CcSEcCtD
Erlotinib—Arthralgia—Docetaxel—melanoma	5.75e-05	0.00102	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	5.71e-05	0.00102	CcSEcCtD
Erlotinib—Dizziness—Carmustine—melanoma	5.67e-05	0.00101	CcSEcCtD
Erlotinib—Diarrhoea—Temozolomide—melanoma	5.67e-05	0.00101	CcSEcCtD
Erlotinib—Oedema—Docetaxel—melanoma	5.51e-05	0.000982	CcSEcCtD
Erlotinib—Dizziness—Temozolomide—melanoma	5.48e-05	0.000977	CcSEcCtD
Erlotinib—Infection—Docetaxel—melanoma	5.48e-05	0.000976	CcSEcCtD
Erlotinib—Vomiting—Carmustine—melanoma	5.45e-05	0.000972	CcSEcCtD
Erlotinib—Nausea—Dactinomycin—melanoma	5.44e-05	0.00097	CcSEcCtD
Erlotinib—ABCG2—lymph node—melanoma	5.43e-05	0.00377	CbGeAlD
Erlotinib—Shock—Docetaxel—melanoma	5.42e-05	0.000966	CcSEcCtD
Erlotinib—Rash—Carmustine—melanoma	5.41e-05	0.000964	CcSEcCtD
Erlotinib—Nervous system disorder—Docetaxel—melanoma	5.41e-05	0.000963	CcSEcCtD
Erlotinib—Dermatitis—Carmustine—melanoma	5.4e-05	0.000963	CcSEcCtD
Erlotinib—Thrombocytopenia—Docetaxel—melanoma	5.4e-05	0.000962	CcSEcCtD
Erlotinib—Headache—Carmustine—melanoma	5.37e-05	0.000957	CcSEcCtD
Erlotinib—Skin disorder—Docetaxel—melanoma	5.36e-05	0.000954	CcSEcCtD
Erlotinib—ABCB1—mammalian vulva—melanoma	5.35e-05	0.00371	CbGeAlD
Erlotinib—CYP2D6—head—melanoma	5.32e-05	0.00369	CbGeAlD
Erlotinib—Vomiting—Temozolomide—melanoma	5.27e-05	0.000939	CcSEcCtD
Erlotinib—Anorexia—Docetaxel—melanoma	5.26e-05	0.000936	CcSEcCtD
Erlotinib—Rash—Temozolomide—melanoma	5.23e-05	0.000931	CcSEcCtD
Erlotinib—Dermatitis—Temozolomide—melanoma	5.22e-05	0.00093	CcSEcCtD
Erlotinib—Headache—Temozolomide—melanoma	5.19e-05	0.000925	CcSEcCtD
Erlotinib—CYP1A1—lymph node—melanoma	5.16e-05	0.00358	CbGeAlD
Erlotinib—Nausea—Carmustine—melanoma	5.1e-05	0.000908	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Docetaxel—melanoma	5.02e-05	0.000895	CcSEcCtD
Erlotinib—Insomnia—Docetaxel—melanoma	4.99e-05	0.000888	CcSEcCtD
Erlotinib—Nausea—Temozolomide—melanoma	4.92e-05	0.000877	CcSEcCtD
Erlotinib—Dyspnoea—Docetaxel—melanoma	4.92e-05	0.000876	CcSEcCtD
Erlotinib—Dyspepsia—Docetaxel—melanoma	4.85e-05	0.000865	CcSEcCtD
Erlotinib—Decreased appetite—Docetaxel—melanoma	4.79e-05	0.000854	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Docetaxel—melanoma	4.76e-05	0.000848	CcSEcCtD
Erlotinib—Fatigue—Docetaxel—melanoma	4.75e-05	0.000847	CcSEcCtD
Erlotinib—Constipation—Docetaxel—melanoma	4.71e-05	0.00084	CcSEcCtD
Erlotinib—Pain—Docetaxel—melanoma	4.71e-05	0.00084	CcSEcCtD
Erlotinib—Gastrointestinal pain—Docetaxel—melanoma	4.51e-05	0.000803	CcSEcCtD
Erlotinib—Body temperature increased—Docetaxel—melanoma	4.36e-05	0.000776	CcSEcCtD
Erlotinib—Abdominal pain—Docetaxel—melanoma	4.36e-05	0.000776	CcSEcCtD
Erlotinib—Asthenia—Docetaxel—melanoma	3.96e-05	0.000705	CcSEcCtD
Erlotinib—Pruritus—Docetaxel—melanoma	3.9e-05	0.000695	CcSEcCtD
Erlotinib—ABCB1—head—melanoma	3.83e-05	0.00266	CbGeAlD
Erlotinib—Diarrhoea—Docetaxel—melanoma	3.77e-05	0.000672	CcSEcCtD
Erlotinib—Dizziness—Docetaxel—melanoma	3.65e-05	0.000649	CcSEcCtD
Erlotinib—Vomiting—Docetaxel—melanoma	3.51e-05	0.000624	CcSEcCtD
Erlotinib—Rash—Docetaxel—melanoma	3.48e-05	0.000619	CcSEcCtD
Erlotinib—Dermatitis—Docetaxel—melanoma	3.47e-05	0.000619	CcSEcCtD
Erlotinib—Headache—Docetaxel—melanoma	3.45e-05	0.000615	CcSEcCtD
Erlotinib—Nausea—Docetaxel—melanoma	3.27e-05	0.000583	CcSEcCtD
Erlotinib—ABCB1—lymph node—melanoma	2.68e-05	0.00186	CbGeAlD
Erlotinib—ABCB1—Metabolism—CD44—melanoma	9.88e-07	1.33e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK3—melanoma	9.82e-07	1.32e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—FASN—melanoma	9.8e-07	1.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—melanoma	9.79e-07	1.31e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCB1—melanoma	9.76e-07	1.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FN1—melanoma	9.73e-07	1.31e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	9.73e-07	1.31e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC5A5—melanoma	9.64e-07	1.29e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—melanoma	9.62e-07	1.29e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	9.59e-07	1.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1B—melanoma	9.56e-07	1.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1A—melanoma	9.56e-07	1.28e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—melanoma	9.55e-07	1.28e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	9.54e-07	1.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—melanoma	9.54e-07	1.28e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK3—melanoma	9.54e-07	1.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOTCH1—melanoma	9.52e-07	1.28e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PRKCA—melanoma	9.51e-07	1.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NFKB1—melanoma	9.49e-07	1.27e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1B1—melanoma	9.47e-07	1.27e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—melanoma	9.46e-07	1.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—melanoma	9.44e-07	1.27e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ERCC2—melanoma	9.43e-07	1.27e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CB—melanoma	9.39e-07	1.26e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—melanoma	9.35e-07	1.26e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK1—melanoma	9.34e-07	1.25e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—melanoma	9.34e-07	1.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CD80—melanoma	9.33e-07	1.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIT—melanoma	9.31e-07	1.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APC—melanoma	9.31e-07	1.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CG—melanoma	9.31e-07	1.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—melanoma	9.31e-07	1.25e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GNAQ—melanoma	9.31e-07	1.25e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CD44—melanoma	9.31e-07	1.25e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—melanoma	9.3e-07	1.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EGF—melanoma	9.21e-07	1.24e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—melanoma	9.2e-07	1.24e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLA2G6—melanoma	9.15e-07	1.23e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CD—melanoma	9.14e-07	1.23e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK1—melanoma	9.07e-07	1.22e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—melanoma	9.07e-07	1.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—melanoma	9.06e-07	1.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—melanoma	9.04e-07	1.21e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—melanoma	9.02e-07	1.21e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PRKCA—melanoma	8.99e-07	1.21e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP17A1—melanoma	8.98e-07	1.21e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK3—melanoma	8.95e-07	1.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—melanoma	8.95e-07	1.2e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1B1—melanoma	8.92e-07	1.2e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK3—melanoma	8.92e-07	1.2e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ERCC2—melanoma	8.91e-07	1.2e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—melanoma	8.9e-07	1.2e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	8.86e-07	1.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1A—melanoma	8.83e-07	1.19e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—melanoma	8.82e-07	1.19e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—melanoma	8.81e-07	1.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—melanoma	8.81e-07	1.18e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CB—melanoma	8.76e-07	1.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—melanoma	8.75e-07	1.18e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	8.75e-07	1.17e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—melanoma	8.68e-07	1.17e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—melanoma	8.57e-07	1.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—melanoma	8.53e-07	1.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1—melanoma	8.53e-07	1.15e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK1—melanoma	8.52e-07	1.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—melanoma	8.51e-07	1.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK1—melanoma	8.49e-07	1.14e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNA11—melanoma	8.48e-07	1.14e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—FASN—melanoma	8.3e-07	1.11e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAP2K1—melanoma	8.24e-07	1.11e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PRKCA—melanoma	8.24e-07	1.11e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—VCAN—melanoma	8.22e-07	1.1e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PRKCA—melanoma	8.19e-07	1.1e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CD—melanoma	8.19e-07	1.1e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ERCC2—melanoma	8.17e-07	1.1e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—melanoma	8.17e-07	1.1e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK3—melanoma	8.15e-07	1.09e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ERCC2—melanoma	8.12e-07	1.09e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—melanoma	8.12e-07	1.09e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—melanoma	8.11e-07	1.09e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—melanoma	8.11e-07	1.09e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—melanoma	8.05e-07	1.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—melanoma	8.02e-07	1.08e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CB—melanoma	7.97e-07	1.07e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—melanoma	7.89e-07	1.06e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CD44—melanoma	7.89e-07	1.06e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNAQ—melanoma	7.89e-07	1.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—melanoma	7.88e-07	1.06e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—melanoma	7.87e-07	1.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—melanoma	7.86e-07	1.06e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—melanoma	7.84e-07	1.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF2—melanoma	7.84e-07	1.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK1—melanoma	7.75e-07	1.04e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	7.72e-07	1.04e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	7.65e-07	1.03e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—melanoma	7.57e-07	1.02e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1B1—melanoma	7.56e-07	1.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK3—melanoma	7.52e-07	1.01e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—melanoma	7.5e-07	1.01e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—melanoma	7.45e-07	1e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—melanoma	7.39e-07	9.93e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.38e-07	9.92e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—melanoma	7.36e-07	9.89e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—melanoma	7.35e-07	9.87e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MDM2—melanoma	7.33e-07	9.85e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—melanoma	7.32e-07	9.84e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—melanoma	7.32e-07	9.83e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—melanoma	7.29e-07	9.79e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—melanoma	7.23e-07	9.71e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—melanoma	7.19e-07	9.66e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—melanoma	7.18e-07	9.64e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PRKCA—melanoma	7.18e-07	9.64e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK1—melanoma	7.16e-07	9.62e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—melanoma	7.15e-07	9.61e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CB—melanoma	7.14e-07	9.59e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ERCC2—melanoma	7.12e-07	9.56e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—melanoma	7.04e-07	9.45e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—melanoma	6.97e-07	9.37e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP17A1—melanoma	6.93e-07	9.31e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—melanoma	6.89e-07	9.25e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—melanoma	6.86e-07	9.21e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—melanoma	6.84e-07	9.19e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—melanoma	6.81e-07	9.15e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—melanoma	6.79e-07	9.12e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.77e-07	9.09e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PRKCA—melanoma	6.76e-07	9.08e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—melanoma	6.76e-07	9.08e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.73e-07	9.04e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—melanoma	6.73e-07	9.04e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ERCC2—melanoma	6.71e-07	9.01e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—melanoma	6.7e-07	9e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	6.67e-07	8.96e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—melanoma	6.62e-07	8.9e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—melanoma	6.56e-07	8.82e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—melanoma	6.55e-07	8.8e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CD—melanoma	6.55e-07	8.8e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNA11—melanoma	6.55e-07	8.79e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—melanoma	6.52e-07	8.76e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—melanoma	6.47e-07	8.68e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—melanoma	6.45e-07	8.67e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—melanoma	6.43e-07	8.64e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—melanoma	6.42e-07	8.62e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FASN—melanoma	6.41e-07	8.61e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—melanoma	6.39e-07	8.58e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—melanoma	6.33e-07	8.5e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—melanoma	6.3e-07	8.46e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—melanoma	6.23e-07	8.37e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—melanoma	6.23e-07	8.36e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—melanoma	6.23e-07	8.36e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—melanoma	6.21e-07	8.34e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—melanoma	6.2e-07	8.33e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—melanoma	6.19e-07	8.32e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CD—melanoma	6.19e-07	8.31e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1A—melanoma	6.18e-07	8.3e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—melanoma	6.17e-07	8.28e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NFKB1—melanoma	6.14e-07	8.24e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—melanoma	6.11e-07	8.2e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNAQ—melanoma	6.09e-07	8.17e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CD44—melanoma	6.09e-07	8.17e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—melanoma	6.04e-07	8.11e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—melanoma	6.02e-07	8.08e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—melanoma	5.96e-07	8e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1B1—melanoma	5.83e-07	7.84e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—melanoma	5.75e-07	7.72e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PRKCA—melanoma	5.73e-07	7.7e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—melanoma	5.72e-07	7.69e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CB—melanoma	5.71e-07	7.67e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ERCC2—melanoma	5.68e-07	7.63e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CD—melanoma	5.67e-07	7.62e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—melanoma	5.66e-07	7.6e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CD—melanoma	5.64e-07	7.58e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—melanoma	5.62e-07	7.55e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—melanoma	5.6e-07	7.52e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—melanoma	5.57e-07	7.48e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—melanoma	5.52e-07	7.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—melanoma	5.5e-07	7.39e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—melanoma	5.5e-07	7.39e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—melanoma	5.5e-07	7.38e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—melanoma	5.43e-07	7.29e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CB—melanoma	5.39e-07	7.24e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—melanoma	5.34e-07	7.18e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—melanoma	5.34e-07	7.17e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—melanoma	5.3e-07	7.12e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK3—melanoma	5.27e-07	7.08e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—melanoma	5.12e-07	6.88e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—melanoma	5.11e-07	6.87e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—melanoma	5.08e-07	6.82e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK1—melanoma	5.01e-07	6.73e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CB—melanoma	4.94e-07	6.64e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CD—melanoma	4.94e-07	6.64e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—melanoma	4.93e-07	6.63e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CB—melanoma	4.92e-07	6.6e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—melanoma	4.9e-07	6.58e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—melanoma	4.88e-07	6.55e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—melanoma	4.87e-07	6.54e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—melanoma	4.86e-07	6.52e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—melanoma	4.81e-07	6.45e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—melanoma	4.74e-07	6.36e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.71e-07	6.32e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—melanoma	4.68e-07	6.28e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—melanoma	4.66e-07	6.26e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CD—melanoma	4.66e-07	6.26e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—melanoma	4.6e-07	6.18e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—melanoma	4.49e-07	6.03e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PRKCA—melanoma	4.42e-07	5.94e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ERCC2—melanoma	4.39e-07	5.89e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—melanoma	4.36e-07	5.86e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—melanoma	4.35e-07	5.84e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—melanoma	4.33e-07	5.82e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CB—melanoma	4.31e-07	5.79e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—melanoma	4.27e-07	5.74e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—melanoma	4.27e-07	5.73e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—melanoma	4.25e-07	5.71e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—melanoma	4.21e-07	5.65e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CB—melanoma	4.06e-07	5.45e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—melanoma	4.02e-07	5.41e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—melanoma	4.02e-07	5.4e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—melanoma	3.97e-07	5.33e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CD—melanoma	3.95e-07	5.3e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—melanoma	3.89e-07	5.23e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—melanoma	3.85e-07	5.17e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—melanoma	3.72e-07	5e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—melanoma	3.55e-07	4.77e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—melanoma	3.51e-07	4.71e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—melanoma	3.48e-07	4.67e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—melanoma	3.46e-07	4.65e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CB—melanoma	3.44e-07	4.62e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—melanoma	3.41e-07	4.58e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—melanoma	3.34e-07	4.49e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—melanoma	3.29e-07	4.42e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CD—melanoma	3.04e-07	4.09e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—melanoma	3.01e-07	4.05e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—melanoma	3.01e-07	4.04e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—melanoma	3e-07	4.03e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—melanoma	2.97e-07	3.99e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—melanoma	2.84e-07	3.82e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—melanoma	2.69e-07	3.61e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CB—melanoma	2.65e-07	3.56e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—melanoma	2.63e-07	3.53e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—melanoma	2.63e-07	3.53e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—melanoma	2.47e-07	3.32e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—melanoma	2.46e-07	3.31e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—melanoma	2.45e-07	3.29e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—melanoma	2.29e-07	3.08e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—melanoma	2.15e-07	2.88e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—melanoma	2.1e-07	2.82e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—melanoma	2.02e-07	2.72e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—melanoma	1.71e-07	2.3e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—melanoma	1.62e-07	2.17e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—melanoma	1.32e-07	1.78e-06	CbGpPWpGaD
